

Applicants: Holloway et al.

Serial No.: 09/941,314

Filed: August 29, 2001

For: MAMMALIAN CYSTATIN-8 AND ITS USE TO INHIBIT CANCER PROCOAGULANT PROTEIN

REMARKS

The Office Action sets forth a restriction requirement under 35 U.S.C. §121.

Applicants were requested to elect one of the four designated groups as briefly noted below:

I. Claim 1, drawn to polynucleotides encoding SEQ ID NO:2, classified in class 536, subclass 23.1.

II. Claim 2, drawn to protein (SEQ ID NO:2), classified in class 530, subclass 350.

III. Claim 3, drawn to antibody, classified in class 530, subclass 387.1.

IV. Claim 4, drawn to a method of inhibiting cancer procoagulant protein using the product of group II above, classified in class 512, subclass 2.

In response to the Requirement for Restriction Election, Applicants elect Group II, claim 2, drawn to protein (SEQ ID NO:2), without traverse. Claims 1, 3 and 4 are withdrawn from consideration in this case; however, Applicants reserve the right to pursue examination of the non-elected claims in continuation or divisional applications.

Applicants: Holloway et al.

Serial No.: 09/941,314

Filed: August 29, 2001

For: MAMMALIAN CYSTATIN-8 AND ITS USE TO INHIBIT CANCER PROCOAGULANT PROTEIN

Early reconsideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6540.

Respectfully Submitted,



Brian J. Walsh
Registration No. 45,543

Enclosures:

- Petition and Fee for Extension of Time (in duplicate)
- Preliminary Amendment
- Power of Attorney
- Amendment Fee Transmittal (in duplicate)
- Postcard